Quote:

---

The Company can immediately initiate enrollment in this Phase 2 clinical trial for the treatment of approximately 22 different solid tumor cancers, including melanoma, brain-glioblastoma, throat, lung , stomach, colon carcinoma, breast, testicular, ovarian, uterine, pancreas, bladder, among other indications. The Company expects to receive preliminary results on each patient within 3 to 4 weeks after the initial treatment with leronlimab. The Company will continue to enroll patients in its metastatic breast cancer trials.

---